![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
BigBear.ai Holdings
BBAI
5
Advanced Micro Devices
AMD
US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 1.170
- +0.010+0.86%
Close Feb 28 16:00 ET
- 1.151
- -0.019-1.61%
Post 20:01 ET
105.95MMarket Cap-0.70P/E (TTM)
1.190High1.110Low1.31MVolume1.170Open1.160Pre Close1.49MTurnover1.67%Turnover RatioLossP/E (Static)90.55MShares7.93052wk High0.38P/B91.44MFloat Cap1.11052wk Low--Dividend TTM78.16MShs Float32.645Historical High--Div YieldTTM6.90%Amplitude1.110Historical Low1.145Avg Price1Lot Size
Caribou Biosciences Stock Forum
Sign in to post a comment
$Caribou Biosciences (CRBU.US)$ Next one to fly 👀.
11
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
$Caribou Biosciences (CRBU.US)$
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
3
15
$Caribou Biosciences (CRBU.US)$ Reuters· just
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
2
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
1
$Caribou Biosciences (CRBU.US)$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud![]()
3
3
$Caribou Biosciences (CRBU.US)$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
2
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
No comment yet
HOHA888 : Hi what do you think is a good TP target? My average is around $1.50
FattyChick OP HOHA888 : >1.70
HOHA888 FattyChick OP : okay thanks!
FattyChick OP HOHA888 : Long term >$6
HOHA888 FattyChick OP : Long term as in? Abt half a year?
View more comments...